Cornely, O. A., Bassetti, M., Calandra, T., Garbino, J., Kullberg, B. J., Lortholary, O., Meersseman, W., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., Bille, J., Castagnola, E., Cuenca-Estrella, M., Donnelly, J. P., Groll, A. H., Herbrecht, R., Hope, W. W., Jensen, H. E., Lass-Floerl, C., Petrikkos, G., Richardson, M. D., Roilides, E., Verweij, P. E., Viscoli, C. and Ullmann, A. J. (2012). ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin. Microbiol. Infect., 18. S. 19 - 38. OXFORD: ELSEVIER SCI LTD. ISSN 1469-0691

Full text not available from this repository.

Abstract

Clin Microbiol Infect 2012; 18 (Suppl. 7): 1937 Abstract This part of the EFISG guidelines focuses on non-neutropenic adult patients. Only a few of the numerous recommendations can be summarized in the abstract. Prophylactic usage of fluconazole is supported in patients with recent abdominal surgery and recurrent gastrointestinal perforations or anastomotic leakages. Candida isolation from respiratory secretions alone should never prompt treatment. For the targeted initial treatment of candidaemia, echinocandins are strongly recommended while liposomal amphotericin B and voriconazole are supported with moderate, and fluconazole with marginal strength. Treatment duration for candidaemia should be a minimum of 14 days after the end of candidaemia, which can be determined by one blood culture per day until negativity. Switching to oral treatment after 10 days of intravenous therapy has been safe in stable patients with susceptible Candida species. In candidaemia, removal of indwelling catheters is strongly recommended. If catheters cannot be removed, lipid-based amphotericin B or echinocandins should be preferred over azoles. Transoesophageal echocardiography and fundoscopy should be performed to detect organ involvement. Native valve endocarditis requires surgery within a week, while in prosthetic valve endocarditis, earlier surgery may be beneficial. The antifungal regimen of choice is liposomal amphotericin B +/- flucytosine. In ocular candidiasis, liposomal amphotericin B +/- flucytosine is recommended when the susceptibility of the isolate is unknown, and in susceptible isolates, fluconazole and voriconazole are alternatives. Amphotericin B deoxycholate is not recommended for any indication due to severe side effects.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Cornely, O. A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bassetti, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Calandra, T.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Garbino, J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kullberg, B. J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lortholary, O.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Meersseman, W.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Akova, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Arendrup, M. C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Arikan-Akdagli, S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bille, J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Castagnola, E.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Cuenca-Estrella, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Donnelly, J. P.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Groll, A. H.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Herbrecht, R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hope, W. W.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Jensen, H. E.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lass-Floerl, C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Petrikkos, G.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Richardson, M. D.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Roilides, E.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Verweij, P. E.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Viscoli, C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ullmann, A. J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-477854
DOI: 10.1111/1469-0691.12039
Journal or Publication Title: Clin. Microbiol. Infect.
Volume: 18
Page Range: S. 19 - 38
Date: 2012
Publisher: ELSEVIER SCI LTD
Place of Publication: OXFORD
ISSN: 1469-0691
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
INTENSIVE-CARE-UNIT; LIPOSOMAL AMPHOTERICIN-B; ENDOGENOUS FUNGAL ENDOPHTHALMITIS; CRITICALLY-ILL PATIENTS; RANDOMIZED CLINICAL-TRIALS; STEM-CELL TRANSPLANTATION; PLACEBO-CONTROLLED TRIAL; CENTRAL VENOUS CATHETER; BLOOD-STREAM INFECTION; RISK SURGICAL-PATIENTSMultiple languages
Infectious Diseases; MicrobiologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/47785

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item